Metastatic melanoma, a deadly form of skin cancer, often develops resistance to the BRAF inhibitor drug vemurafenib, highlighting the need for understanding the underlying mechanisms of resistance and exploring potential therapeutic strategies targeting integrins and TGF-β signalling. In this study, the role of integrins and TGF-β signalling in vemurafenib resistance in melanoma was investigated, and the potential of combining vemurafenib with cilengitide as a therapeutic strategy was investigated. In this study, it was found that the transcription of and was induced by acquired vemurafenib resistance, and levels were increased as a result of this resistance. The transcription of was mediated by the TGF-β pathway in the development of vemurafenib resistance. A synergistic effect on the proliferation of vemurafenib-resistant melanoma cells was observed with the combination therapy of vemurafenib and cilengitide. Additionally, this combination therapy significantly decreased invasion and colony formation in these resistant cells. In conclusion, it is suggested that targeting integrins and TGF-β signalling, specifically , , , and , may offer promising approaches to overcoming vemurafenib resistance, thereby improving outcomes for metastatic melanoma patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11277089 | PMC |
| http://dx.doi.org/10.3390/ijms25147946 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Inhibition of glutaminase elicits senolysis in therapy-induced senescent melanoma cells.
Cell Death Dis
December 2024
Department of Dermatology, Case Western Reserve University and University Hospitals Cleveland Medical Center, Cleveland, OH, 44106, USA.
The cyclin D1-Cyclin-Dependent Kinases 4 and 6 (CDK4/6) complex is crucial for the development of melanoma. We previously demonstrated that targeting CDK4/6 using small molecule inhibitors (CDK4/6i) suppresses Braf melanoma growth in vitro and in vivo through induction of cellular senescence. However, clinical trials investigating CDK4/6i in melanoma have not yielded successful outcomes, underscoring the necessity to enhance the therapeutic efficacy of CDK4/6i.
View Article and Find Full Text PDFInterfering Nuclear Protein Laminb1 Induces DNA Damage and Reduces Vemurafenib Resistance in Melanoma Cells In Vitro.
Cancers (Basel)
December 2024
Bioinspired Engineering and Biomechanics Center (BEBC), Xi'an Jiaotong University, Xi'an 710049, China.
Background/objectives: Drug resistance poses a substantial clinical challenge in melanoma treatment, yet the underlying mechanism remains elusive. Here, we report the novel role of laminB1, a nuclear structure protein, in regulating the response of BRAF-mutated melanoma cells to vemurafenib.
Results: Our analysis of clinical samples and existing databases highlights the tight correlation between the laminB1 expression level and melanoma progression and prognosis.
The evolution of BRAF-targeted therapies in melanoma: overcoming hurdles and unleashing novel strategies.
Front Oncol
November 2024
Department of Biochemistry, Faculty of Medicine, Medical University of Warsaw, Warsaw, Poland.
Melanoma, a highly aggressive form of skin cancer, poses a significant global health burden, with 331,647 new cases and 58,645 deaths reported in 2022. The development of melanoma is influenced by various factors, including sunlight exposure and BRAF mutations that activate the MAPK/ERK pathway. The introduction of BRAF and MEK inhibitors has revolutionized the treatment landscape for melanoma patients.
View Article and Find Full Text PDFA comprehensive review of targeting RAF kinase in cancer.
Eur J Pharmacol
January 2025
Department of Pharmacy, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj, 8100, Bangladesh. Electronic address:
Article Synopsis
- RAF kinases, especially BRAF, are essential in the MAPK/ERK signaling pathway, influencing cell growth and survival; mutations in the BRAF gene can lead to cancer, particularly melanoma with the BRAF-V600E mutation.
- Targeted therapies like vemurafenib and dabrafenib have shown significant success in treating BRAF-V600E-mutant melanomas and some other cancers, improving patient outcomes despite their challenges.
- Therapeutic resistance is a major issue due to mechanisms like RAF dimerization and pathway reactivation, prompting research into combination therapies and new RAF inhibitors to enhance treatment effectiveness and specificity.
FOXN3 Regulates Autophagic Activity to Suppress Drug Resistance in Melanoma Cells.
Clin Cosmet Investig Dermatol
November 2024
Department of Dermatology, Xi'an Jiaotong University The Second Affiliated Hospital, Xi'an, Shaanxi, People's Republic of China.
Background: The forkhead box (FOX) family member FOXN3 has been reported to inhibit transcriptional activity associated with regulating tumor development. However, the role of FOXN3 in the pathogenesis of melanoma is not well understood.
Objective: To investigate the biological functions of FOXN3 in drug resistance of melanoma.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!